Schizophrenia is a pervasive neuropsychiatric disease of uncertain cause that affects approximately 1% of the adult population in the United States and Europe. An increased occurrence of schizophrenia in family members of affected persons suggests that genetic factors play a role in its etiology, and some candidate predisposing genes have been identified. Environmental factors are also important. Epidemiologic studies, for example, have established that winter-spring birth, urban birth, and perinatal and postnatal infection are all risk factors for the disease developing in later life. These studies have rekindled an interest in the role of infectious agents in schizophrenia, a concept first proposed in 1896 ([@R1]). This review focuses on evidence specifically linking infection with *Toxoplasma gondii* to the etiology of some cases of schizophrenia.

*T. gondii* is an intracellular parasite in the phylum Apicomplexa. Its life cycle can be completed only in cats and other felids, which are the definitive hosts. However*, T. gondii* also infects a wide variety of intermediate hosts, including humans. In many mammals, *T. gondii* is known to be an important cause of abortions and stillbirths and to selectively infect muscle and brain tissue. A variety of neurologic symptoms, including incoordination, tremors, head-shaking, and seizures, have been described in sheep, pigs, cattle, rabbits, and monkeys infected with *T. gondii* ([@R2]).

Humans may become infected by contact with cat feces or by eating undercooked meat. The importance of these modes of transmission may vary in different populations ([@R3]). Individual response to *Toxoplasma* infection is determined by immune status, timing of infection, and the genetic composition of the host and the organism ([@R4]).

*Toxoplasma* organisms have also been shown to impair learning and memory in mice ([@R5]) and to produce behavioral changes in both mice and rats. Of special interest are studies showing that *Toxoplasma-*infected rats become less neophobic, leading to the diminution of their natural aversion to the odor of cats ([@R6]). These behavioral changes increase the chances that the rat will be eaten by a cat, thus enabling *Toxoplasma* to complete its life cycle, an example of evolutionarily driven manipulation of host behavior by the parasite.

In humans*, Toxoplasma* is an important cause of abortions and stillbirths after primary infection in pregnant women. The organism can also cross the placenta and infect the fetus. The symptoms of congenital toxoplasmosis include abnormal changes in head size (hydrocephaly or microcephaly), intracranial calcifications, deafness, seizures, cerebral palsy, damage to the retina, and mental retardation. Some sequelae of congenital toxoplasmosis are not apparent at birth and may not become apparent until the second or third decade of life. Hydrocephalus ([@R7]), increased ventricular size ([@R8]), and cognitive impairment ([@R9]) have also been noted in some persons with schizophrenia and other forms of psychosis.

Some cases of acute toxoplasmosis in adults are associated with psychiatric symptoms such as delusions and hallucinations. A review of 114 cases of acquired toxoplasmosis noted that "psychiatric disturbances were very frequent" in 24 of the case-patients ([@R10]). Case reports describe a 22-year-old woman who exhibited paranoid and bizarre delusions ("she said she had no veins in her arms and legs"), disorganized speech, and flattened affect; a 32-year-old woman who had auditory and visual hallucinations; and a 34-year-old woman who experienced auditory hallucinations and a thought disorder ([@R11]). Schizophrenia was first diagnosed in all three patients, but later neurologic symptoms developed, which led to the correct diagnosis of *Toxoplasma* encephalitis.

Psychiatric manifestations of *T. gondii* are also prominent in immunocompromised persons with AIDS in whom latent infections have become reactivated. Reviews of such AIDS cases with toxoplasmosis have indicated that altered mental status may occur in as many as 60% of patients and that the symptoms may include delusions, auditory hallucinations, and thought disorders ([@R12]).

Additional studies have documented that persons with serologic evidence of *Toxoplasma* infection have evidence of psychiatric changes in the absence of a history of clinically apparent *Toxoplasma* infection. Studies in which personality questionnaires have been administered to healthy adults have indicated that serum antibodies to *T. gondii* are associated with alterations in behavior and psychomotor skills ([@R13]). Seropositivity to *Toxoplasma* has also been associated with "lack of energy or tiredness" in schoolchildren ([@R14]). In view of these findings, we decided to carry out serologic and other studies and to survey the literature for possible additional links between *Toxoplasma* infection and schizophrenia.

Serologic Studies of Patients with Schizophrenia
================================================

Studies Done Before 1980
------------------------

In the course of doing our studies, we discovered that much research had been published in languages other than English and was not listed on searchable databases. Through direct contact with authors and by obtaining references listed on their papers, we identified 13 relevant studies published between 1953 and 1979 ([@R15]--[@R27]), as listed on the [Table](#T1){ref-type="table"}. Some publication bias is likely, since negative studies are less likely to have been submitted or published.

###### Toxoplasmosis antibody studies of psychiatric patients

  Y                    Author and country                        Test used              Patients                                       Controls                                                \% Patients antibody positive     \% Controls antibody positive   p value chi square
  -------------------- ----------------------------------------- ---------------------- ---------------------------------------------- ------------------------------------------------------- --------------------------------- ------------------------------- --------------------
  [Before 1980]{.ul}                                                                                                                                                                                                                                             
  1953                 Kozar (15) Poland                         Skin test              Psychiatric inpatients, all diagnoses          Healthy persons, ages 18--60                            52 (495/961)                      25 (170/681)                    \<0.0001
  1956                 Vojtechovská et al. (16) Czechoslovakia   Skin test              Inpatients with "psychosis"                    General population                                      59 (68/116)                       30 (not specified)              \<0.0001
  1956                 Wende (17) East Germany                   Dye test               Inpatients with schizophrenia                  Inpatients with neurologic disorders                    8 (3/38)                          5 (24/520)                      0.418
  1957                 Jirovec et al. (18) Czechoslovakia        Skin test              Inpatients with schizophrenia                  Normal population                                       48 (238/501)                      29 (286/970)                    \<0.0001
  1958                 Buentello (19) Mexico                     Color change in fish   Inpatients with schizophrenia                  Normal subjects                                         69 (29/42)                        0 (0/60)                        \<0.0001
  1958                 Caglieris (20) Italy                      Dye test               Inpatients with schizophrenia                  Normal subjects                                         21 (13/61)                        15 (12/81)                      0.376
  1961                 Cook & Derrick (21) Australia             Dye test C.F.          Inpatients with schizophrenia                  General population                                      36 (19/53) ≥1:16 11 (6/53) ≥1:4   24 (182/760) 13 (99/760)        0.053 0.840
  1962                 Yegerov et al. (22) Russia                Skin test C.F.         Inpatients with schizophrenia                  Hospital employees                                      19 (7/37) 32 (12/37)              4 (1/25) 28 (7/25)              0.124 0.784
  1962                 Avlavidov (23) Bulgaria                   Skin test C.F.         Psychiatric inpatients, not specified          Female surgical patients                                26 (5/19) 21 (3/14)               3 (1/35) 9 (3/34)               0.017 0.339
  1966                 Berengo et al. (24) Italy                 Dye test               Inpatients with schizophrenia                  General population                                      14 (76/560)                       4% (49/1200)                    \<0.0001
  1966                 Roch & Varela (25) Mexico                 Dye test               Schizophrenia, hospital status not specified   General population                                      86% (836/973)                     30% (4,411/14,689)              \<0.0001
  1968                 Garrido & Redondo (26) Spain              C.F.                   Inpatients with schizophrenia                  General population                                      44 (17/39)                        29 (147/500)                    0.072
  1979                 Garcia (27) Cuba                          Skin test              Psychiatric inpatients                         Normal persons                                          60 (60/100)                       30 (30/100)                     \<0.0001
  [Since 1999]{.ul}                                                                                                                                                                                                                                              
  1999                 Qiuying et al. (28) China                 EIA                    Inpatients with schizophrenia                  Normal persons from same region for routine physicals   14 (22/152)                       10 (41/396)                     0.181
  2001                 Gu et al. (29) China                      EIA                    First-episode schizophrenia                    Normal controls matched for age, sex, birthplace        33 (45/135)                       9 (4/43)                        0.002
  2001                 Yolken et al. (30) Germany                EIA: IgG or IgM        First-episode schizophrenia                    Normal controls matched for age, sex, SES               42 (16/38)                        11 (3/27)                       0.007
  2002                 Boronow et al. (31) United States         EIA                    Outpatients with schizophrenia                 Normal controls matched for age                         12 (28/229)                       7 (7/100)                       0.147
  2003                 Leweke et al. (32) Germany                EIA                    First-episode schizophrenia, never treated     Normal controls matched for age, sex, SES               36 (13/36)                        14 (10/73)                      \<0.007
  2003                 Torrey & Yolken (unpub. data) Ireland     EIA                    Inpatients with schizophrenia                  Hospital employees                                      60 (31/52)                        45 (9/20)                       0.299

C.F., complement fixation; EIA, enzyme immunoassay; Ig, immunoglobulin; SES, socioeconomic status.

The 13 studies used a variety of immunologic methods for measuring antibodies, including the Sabin Feldman dye test, skin tests, and complement fixation (CF). One study used a test in which an alkaloid from *T. gondii* caused a tropical fish, *Lebistes reticulatus*, to change color ([@R19]). Some of the studies compared the relative efficacy of two different tests. Most of the studies defined *Toxoplasma-*positive results as the presence of a skin reaction or antibodies above a certain titer but often without specifying the precise details of the method; thus, comparing the older studies with each other was not possible. Most of these studies also did not specify what diagnostic criteria were used for schizophrenia, but since at least 12 of them used inpatients, the patients likely had a severe psychiatric disorder. Similarly, most of the studies did not specify the origin of their control group other than saying such things as "681 healthy persons working or studying in the city of Gdansk" ([@R15]).

Despite these limitations, 12 of the 13 studies found that the patient group had a higher percentage of antibodies to *Toxoplasma* than the control group. In eight of the studies, the increase was statistically significant by chi square at the level of p \<0.05. In the two largest studies, Kozar ([@R15]) in Poland reported antibodies in 495 (52%) of 961 psychiatric inpatients compared with 170 (25%) of 681 controls, and Roch and Varela ([@R25]) in Mexico found antibodies in 836 (86%) of 973 patients with schizophrenia compared with finding antibodies in 30% of the general population.

Studies Since 1999
------------------

We identified no studies that were done between 1979 and 1999. Since that time, six studies have been carried out, including our own ([@R28]--[@R32]). All used enzyme immunoassay methods for measuring antibodies to *Toxoplasma.* All of the studies also used modern diagnostic criteria for schizophrenia; three studies included patients with chronic disease, and three included patients who were in the first episode of the disease. All of the studies identified their control groups, and some attempts were made to match them to the patient groups.

The results of these studies are summarized in the [Table](#T1){ref-type="table"}. In all of the studies, the patients had more antibodies to *Toxoplasma* than the control groups, and in the three studies, carried out in China and Germany, of patients who were having their first-episode of schizophrenia, the differences were statistically significant. One of the first-episode studies, carried out in Cologne by Leweke et al. ([@R32]), divided the first-episode patients into those who had never received antipsychotic treatment and those who had received some treatment. The antibody levels for the treated group were intermediate between the levels of the never-treated group and those of the control group, suggesting that antipsychotic medication may have decreased the antibody levels. This conclusion is supported by a study that indicated that some antipsychotic medications inhibit the growth of *T. gondii* in cell culture ([@R33]).

The Leweke et al. study also collected cerebrospinal fluid (CSF) from the first-episode patients. The level of *Toxoplasma* antibody in the CSF of untreated patients was significantly higher than the normal controls (p\<0.0001) ([@R32]). Treated first-episode patients had CSF antibody levels intermediate between those of the untreated patients and the controls, just as was found for the sera.

In addition to these studies on adults with schizophrenia, a study was also conducted by analyzing on serum samples from pregnant women, obtained shortly before delivery, who gave birth to children in whom schizophrenia or other psychoses developed. Preliminary analysis indicates an increased rate of immunoglobulin (Ig) M (but not IgG) class antibodies to *Toxoplasma gondii* in mothers with infants in whom schizophrenia developed later, suggesting that the mothers were experiencing an active infection or that they had persistent IgM antibodies, as described in other studies. Increased levels of IgM antibodies were not found to other perinatal pathogens such as rubella virus or cytomegalovirus ([@R34]).

Discussion
==========

Multiple studies have demonstrated that the brains of persons with schizophrenia show structural and functional changes and that these exist even in patients who have never been treated with antipsychotic medications ([@R35]). Thus, schizophrenia, like multiple sclerosis and Parkinson disease, is a chronic disease of the central nervous system; as with other such diseases, infectious agents should be considered as possible etiologic agents, perhaps in persons who also have an increased genetic susceptibility.

*T. gondii* is of special interest because of its known affinity for brain tissue and its capacity for long-term infection starting in early life. The effect of *Toxoplasma* infection on any given person may differ, depending on such factors as individual genetic predisposition, the state of the immune system, the dose, the virulence of the infecting strain, the timing (e.g., infections in the first trimester of pregnancy differ from those in the third trimester; prenatal and postnatal infections differ; etc.), and the part of the brain affected.

If *Toxoplasma* is involved in the etiology of schizophrenia, however, its synergy with genes may determine the person's brain development, immune response to infections, and response to other infectious agents. The fact that *T. gondii* has been shown to activate retroviruses in animal model systems may be relevant ([@R36]). This property is consistent with the recent finding that many persons with schizophrenia exhibit increased retroviral activation within their central nervous systems ([@R37]).

Numerous studies indicate that, although the symptoms of schizophrenia generally do not manifest until late adolescence or early adulthood, the disease process has its origins in earlier stages of brain development. The ability of *Toxoplasma* organisms to infect the perinatal brain is thus consistent with this aspect of schizophrenia pathogenesis. However, prospective studies also support a possible role of postnatal infections in some cases of schizophrenia ([@R38]). The potential effects of the transmission of *Toxoplasma* in early childhood or later in life should thus be considered.

Epidemiologically, two studies have reported that adults who have schizophrenia or bipolar disorder had a greater exposure to cats in childhood. In one study, 84 (51%) of the 165 affected versus 65 (38%) of the 165 matched controls had owned a house cat in childhood (p = 0.02) ([@R39]). In the other study, 136 (52%) of the 262 affected versus 219 (42%) of the 522 matched controls owned a cat between birth and age 13 (odds ratio 1.53; p\<0.007) ([@R40]). Whether any geographic association exists between the prevalence of toxoplasmosis and the prevalence of schizophrenia is unknown. France, which has a high prevalence of *Toxoplasma-*infected persons, was reported to have first-admission rates for schizophrenia approximately 50% higher than those in England ([@R41]). Ireland also has a high rate of *Toxoplasma-*infected persons in rural areas ([@R42]), confirmed by the high rate of infection in hospital personnel in our own study. The area of our study in Ireland has also been reported to have a high prevalence of schizophrenia ([@R43]).

Neuropathologically, studies of *T. gondii* in cell culture have shown that glial cells, especially astrocytes, are selectively affected ([@R44],[@R45]). Postmortem studies of schizophrenic brains have also reported many glial abnormalities ([@R46]), including decreased numbers of astrocytes ([@R47]). Similarly, animal studies of *Toxoplasma* infections have demonstrated that this organism affects levels of dopamine, norepinephrine, and other neurotransmitters, which are well known to be affected in persons with schizophrenia.

Few data exist concerning the clinical correlates of *Toxoplasma* infection in persons with schizophrenia. A recent study found that persons with schizophrenia who have serologic evidence of *Toxoplasma* infection have increased levels of cognitive impairment compared to age-matched *Toxoplasma*-seronegative patients with similar degrees of psychotic symptoms ([@R31]). Additional studies are needed on the possible associations between *Toxoplasma* infections and the symptoms or clinical course of schizophrenia and other psychiatric diseases.

One limitation of studies of *Toxoplasma* infection and schizophrenia is that one cannot conclusively rule out disease-related differential exposure to the organism. Thus, hospitalized patients may be fed undercooked meat, thereby increasing their seropositivity. Alternatively, the authors of one of the studies speculated that the increased patient seropositivity might have been because the patients worked in the hospital gardens, which were also frequented by cats ([@R21]). The possible effects of hospitalization, altered behavior, or other artifactual factors on seropositivity can be minimized by the analysis of persons with the recent onset of symptoms, as three studies described above have done.

Studies are ongoing in attempts to better define the relationship of *Toxoplasma* infection to schizophrenia. An initial study of the orbital frontal cortex of 14 persons with schizophrenia ([@R48]), in which primers to *T. gondii* were used*,* did not detect sequences. Studies should also include organisms such as *Neospora caninum* and *Hammondi hammondi,* which are closely related to *T. gondii* and which cross-react serologically ([@R49]); *N. caninum* has been detected in human specimens in our laboratory and by others ([@R50]). The use of organism-specific antigens generated from molecular cloning and the use of stage-specific antibodies should help elucidate both the specificity and the timing of the infection.

Finally, clinical trials are under way of antimicrobial drugs with anti-*Toxoplasma* activity, such as trimethoprim-sulfamethoxazole and azithromycin, as adjunctive treatment for persons with schizophrenia in double-blind trials. These studies may lead to new methods for the treatment of schizophrenia and other psychiatric disorders that may be associated with *Toxoplasma* and related organisms.
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